PL342843A1 - Novel compounds and their use as positive ampa receptor modulators - Google Patents

Novel compounds and their use as positive ampa receptor modulators

Info

Publication number
PL342843A1
PL342843A1 PL99342843A PL34284399A PL342843A1 PL 342843 A1 PL342843 A1 PL 342843A1 PL 99342843 A PL99342843 A PL 99342843A PL 34284399 A PL34284399 A PL 34284399A PL 342843 A1 PL342843 A1 PL 342843A1
Authority
PL
Poland
Prior art keywords
novel compounds
receptor modulators
ampa receptor
positive ampa
positive
Prior art date
Application number
PL99342843A
Other languages
English (en)
Inventor
Alex Haahr Gouliaev
Mogens Larsen
Thomas Varming
Claus Mathiesen
Tina Holm Johansen
Jorgen Schell-Krueger
Gunnar M Olsen
Elsebet Ostergaard Nielsen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of PL342843A1 publication Critical patent/PL342843A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/28—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL99342843A 1998-02-18 1999-02-18 Novel compounds and their use as positive ampa receptor modulators PL342843A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK22698 1998-02-18
PCT/DK1999/000070 WO1999042456A2 (en) 1998-02-18 1999-02-18 Novel compounds and their use as positive ampa receptor modulators

Publications (1)

Publication Number Publication Date
PL342843A1 true PL342843A1 (en) 2001-07-16

Family

ID=8091151

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99342843A PL342843A1 (en) 1998-02-18 1999-02-18 Novel compounds and their use as positive ampa receptor modulators

Country Status (17)

Country Link
EP (1) EP1071426A2 (is)
JP (1) JP2002504481A (is)
CN (1) CN1293665A (is)
AU (1) AU751384B2 (is)
CA (1) CA2320354A1 (is)
EE (1) EE200000468A (is)
HU (1) HUP0101280A3 (is)
IL (1) IL137720A0 (is)
IS (1) IS5581A (is)
NO (1) NO20004121L (is)
NZ (1) NZ506251A (is)
PL (1) PL342843A1 (is)
RU (1) RU2214405C2 (is)
SK (1) SK11892000A3 (is)
TR (1) TR200002427T2 (is)
WO (1) WO1999042456A2 (is)
ZA (1) ZA991301B (is)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
FR2812291B1 (fr) * 2000-07-28 2002-12-13 Adir Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1314351A (zh) * 2001-03-22 2001-09-26 刘志红 喹唑啉酮合成方法及具有抗癌作用的一类喹唑啉酮化合物
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
JP4435562B2 (ja) * 2001-06-14 2010-03-17 ナームローゼ・フエンノートチヤツプ・オルガノン （ピリド／チエノ）−［ｆ］−オキサゼピン−５−オン誘導体
JP2005508352A (ja) 2001-10-10 2005-03-31 ニューロサーチ、アクティーゼルスカブ 新規ベンゾチアジン誘導体、その製造方法及びその使用方法
EP1448537A4 (en) * 2001-11-26 2005-05-04 Cortex Pharma Inc CARBONYLBENZOXAZINIC COMPOUNDS ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES
FR2833956B1 (fr) * 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2833955B1 (fr) 2001-12-21 2004-01-30 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2833950B1 (fr) * 2001-12-21 2005-12-16 Servier Lab Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2854634B1 (fr) * 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2856065B1 (fr) * 2003-06-13 2005-08-19 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2856064B1 (fr) * 2003-06-13 2005-08-19 Servier Lab Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP1644369A2 (en) 2003-07-02 2006-04-12 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
CA2536975A1 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
FR2865474B1 (fr) * 2004-01-26 2008-06-13 Servier Lab Nouveaux derives de benzothiazines fluorees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2877338B1 (fr) 2004-11-03 2007-01-26 Servier Lab Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2877342B1 (fr) 2004-11-03 2007-01-26 Servier Lab Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2879201B1 (fr) 2004-12-10 2007-02-16 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE421518T1 (de) 2005-02-10 2009-02-15 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren
WO2006091716A2 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
US8173644B2 (en) 2007-01-03 2012-05-08 Les Laboratoires Servier 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en) 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
FR2933698A1 (fr) 2008-07-09 2010-01-15 Servier Lab Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2943342B1 (fr) * 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
RS56410B1 (sr) 2009-07-27 2018-01-31 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
FR2955107B1 (fr) 2010-01-08 2012-03-02 Servier Lab Nouveaux derives thiochromanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2955106B1 (fr) 2010-01-08 2011-12-23 Servier Lab Nouveaux derives de benzothiadiazines cyclopropylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102958919A (zh) * 2010-07-02 2013-03-06 霍夫曼-拉罗奇有限公司 新的四氢喹啉衍生物
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
FR2964969B1 (fr) * 2010-09-16 2012-08-24 Servier Lab Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IT1402905B1 (it) * 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
JP5934787B2 (ja) 2011-05-10 2016-06-15 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (is) 2011-07-01 2018-04-28
CN102977054A (zh) * 2012-12-12 2013-03-20 中国药科大学 一类选择性α2A受体激动剂的治疗阿尔茨海默病用途
PT3004082T (pt) 2013-05-30 2017-11-13 Idorsia Pharmaceuticals Ltd Moduladores do receptor de cxcr7
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
CN103275016B (zh) * 2013-06-04 2015-03-11 温州医科大学附属第二医院 一种2-取代喹唑啉化合物的合成方法
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
CN103319381B (zh) * 2013-06-14 2014-08-27 湖州康企药业有限公司 一种高纯度精磺胺的制备方法
CN103772296B (zh) * 2013-12-19 2015-06-17 安徽师范大学 一种喹唑啉衍生物的合成方法
WO2016087370A1 (en) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
CN105294599B (zh) * 2015-09-17 2017-09-22 三峡大学 一种噻二嗪类化合物及其不对称的合成方法
CN106946920A (zh) * 2017-04-05 2017-07-14 泰力特医药（湖北）有限公司 一种4‑氨基苯硼酸衍生物的制备方法
WO2020253862A1 (zh) * 2019-06-21 2020-12-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
RU2726456C1 (ru) * 2019-10-02 2020-07-14 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)
CN111100042B (zh) * 2019-11-18 2022-05-31 苏州诚和医药化学有限公司 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
CN111018750B (zh) * 2019-12-19 2022-05-27 苏州诚和医药化学有限公司 一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
WO2024115797A2 (en) * 2022-12-30 2024-06-06 Aexon Labs. Inc. Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275625A (en) * 1966-09-27 Derivatives of
NL296964A (is) *
FR1217929A (fr) * 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
GB863474A (en) * 1958-08-13 1961-03-22 Knud Abildgaard Benzothiadiazine derivatives and their preparation
DE1125938B (de) * 1960-02-12 1962-03-22 Thomae Gmbh Dr K Verfahren zur Herstellung von 7-Sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazin-1, 1-dioxyden
GB946864A (en) * 1960-05-06 1964-01-15 Knud Abildgaard Method for the production of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxides
US3419552A (en) * 1961-04-12 1968-12-31 Lilly Co Eli Preparation of substituted dihydrobenzothiadiazine-1,1-dioxides
CH475269A (de) * 1962-04-19 1969-07-15 Hans Voigt Chem Pharm Fabrik D Verfahren zur Herstellung von 7-Sulfonamido-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyden
US3351595A (en) * 1962-12-07 1967-11-07 Ciba Geigy Corp Derivatives of 3, 4-dihydro-2h-1, 2, 4-benzothiadiazine-1, 1-dioxide
US3311620A (en) * 1963-05-31 1967-03-28 Stanley C Bell Fused ring benzothiadiazines
US3277086A (en) * 1964-07-07 1966-10-04 American Home Prod 1, 2, 4-benzothiadiazine 1, 1-dioxides having a heterocyclic ring fused to the "b" face thereof
US4184039A (en) * 1977-12-01 1980-01-15 Paul Finkelstein Benzothiadiazine 1, 1-dioxides
CA2130096A1 (fr) * 1992-04-15 1993-10-28 Jean-Claude Aloup Derives d'acide 3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxyde-3-carboxylique, leur preparation et les medicaments les contenant
US5488049A (en) * 1993-12-10 1996-01-30 Fidia - Georgetown Institute For The Neuro-Sciences Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents
FR2722502B1 (fr) * 1994-07-12 1996-08-23 Adir Nouveau derive de benzothiadiazine, son procede depreparation et les compositions pharmaceutiques qui le contiennent
JP2000507212A (ja) * 1996-01-29 2000-06-13 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 性機能不全の治療方法
WO1998012185A1 (en) * 1996-09-17 1998-03-26 The Regents Of The University Of California Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor

Also Published As

Publication number Publication date
CA2320354A1 (en) 1999-08-26
HUP0101280A3 (en) 2003-02-28
TR200002427T2 (tr) 2001-01-22
EE200000468A (et) 2002-04-15
NO20004121D0 (no) 2000-08-17
IL137720A0 (en) 2001-10-31
RU2214405C2 (ru) 2003-10-20
AU2512399A (en) 1999-09-06
IS5581A (is) 2000-08-04
SK11892000A3 (sk) 2001-02-12
EP1071426A2 (en) 2001-01-31
HUP0101280A2 (hu) 2001-10-28
NO20004121L (no) 2000-10-17
NZ506251A (en) 2003-01-31
ZA991301B (en) 1999-09-13
JP2002504481A (ja) 2002-02-12
WO1999042456A3 (en) 1999-10-07
AU751384B2 (en) 2002-08-15
WO1999042456A2 (en) 1999-08-26
CN1293665A (zh) 2001-05-02

Similar Documents

Publication Publication Date Title
PL342843A1 (en) Novel compounds and their use as positive ampa receptor modulators
EP1085887A4 (en) NEW ANGIOTENS IN RECEPTOR MODULATORS AND THEIR USE
EP0965321A4 (en) COMPOSITION FOR EXTERNAL USE
GB9704524D0 (en) Composition
GB9715203D0 (en) Composition
GB9713620D0 (en) Composition
GB9711683D0 (en) Composition
GB9715489D0 (en) Composition
GB9714010D0 (en) Composition
EP0973800A4 (en) NEW RECEIVER
EP0958806A4 (en) HAIR COLORING COMPOSITION
PL348504A1 (en) Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
GB2331540B (en) Pavement construction
GB9714998D0 (en) Construction block composition
GB9701031D0 (en) Composition
GB9726284D0 (en) Composition
GB9819420D0 (en) Novel receptor
ZA985013B (en) Paving
AU6427798A (en) Calcium composition
GB9705110D0 (en) Composition
EG23068A (en) Pesticidale composition
GB9702757D0 (en) Plaster composition
ZA984983B (en) Pavement construction
GB9723508D0 (en) Novel use
GB9713471D0 (en) Novel use